Skip to main content

Table 1 Clinical and paraclinical data as well as therapeutic details for jDM and aDM patients

From: Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis

Age (mean ± SD)   juvenile (n = 15) adult (n = 21) NC (n = 10)
8 +/4 years 57 +/15 years 7 +/6 years and 45 +/11 years
Gender female 47 % (7) 67 % (14) 30 % (3)
male 53 % (8) 33 % (7) 70 % (7)
Biopsy location M. deltoideus   57 % (12) 50 % (5)
M. quadriceps 87 % (13) 5 % (1)  
unknown 13 % (2) 38 % (8) 50 % (5)
CK normal 20 % (3) 14 % (3) 100 % (10)
>1-fold 60 % (9) 29 % (6)  
>10-fold 13 % (2) 38 % (8)
unknown 7 % (1) 19 % (4)
Symptoms typical skin rash 73 % (11) 52 % (11)  
dysphagia 20 % (3) 10 % (2) 20 % (2)a
muscle weakness 73 % (11) 67 % (14) 20 % (2)a
muscle pain 60 % (9) 52 % (11) 50 % (5)a
others 27 % (4) 38 % (8)  
unknown 13 % (2) 5 % (1)
Duration of in months 5 +/4 (11) 3 +/3 (10) 7 +/1 (4)
symptoms >1 years 7 % (1) 5 % (1) 20 % (2)
unknown 20 % (3) 48 % (10) 19 % (4)
Tubuloreticular formations (EM) positive 53 % (8) 76 % (16) n.d.
unknown 47 % (7) 24 % (5)  
MSAs positive 7 % (1) 19 % (4) n.d.
negative 67 % (10) 33 % (7)  
unknown 26 % (4) 48 % (10)
Clinical outcome remission 53 % (8) 29 % (6)  
improvement 20 % (3) 10 % (2)
remitting-relapsing 27 % (4) 10 % (2)
no improvement 0 % (0) 5 % (1)  
unknown 0 % (0) 48 % (10) 100 % (10)
  1. asubjective complaints which could not be substantiated by clinical or ancillary exams, n.d. not done